Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06714266 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

DRUG: Trilaciclib

Sponsor

Shandong Cancer Hospital and Institute